Short Report: Epidemiology

Changes in physical activity and modelled cardiovascular risk following diagnosis of diabetes: 1-year results from the ADDITION-Cambridge trial cohort

A. Barakat^{1,2}, K. M. Williams³, A. T. Prevost^{3,4}, A.-L. Kinmonth³, N. J. Wareham², S. J. Griffin² and R. K. Simmons²

¹Department of Health Sciences and EMGO Institute for Health and Care Research, VU University Medical Centre, Amsterdam, The Netherlands, ²MRC Epidemiology Unit, Cambridge, ³General Practice and Primary Care Research Unit, Institute of Public Health, Cambridge and ⁴King's College London, Department of Primary Care and Public Health Sciences, London, UK

Accepted 17 August 2012

Abstract

Aims To describe change in physical activity over 1 year and associations with change in cardiovascular disease risk factors in a population with screen-detected Type 2 diabetes.

Methods Eight hundred and sixty-seven individuals with screen-detected diabetes underwent measurement of self-reported physical activity, cardiovascular disease risk factors and modelled cardiovascular disease risk at baseline and 1 year (n = 736) in the ADDITION-Cambridge trial. Multiple linear regression was used to quantify the association between change in different physical activity domains and cardiovascular disease risk factors at 1 year.

Results There was no change in self-reported physical activity over 12 months. Even relatively large changes in physical activity were associated with relatively small changes in cardiovascular disease risk factors after allowing for changes in self-reported medication and diet. For every 30 metabolic equivalent-h increase in recreational activity (equivalent to 10 h/brisk walking/week), there was an average reduction of 0.1% in HbA_{1c} in men (95% CI –0.15 to –0.01, P = 0.021) and an average reduction of 2 mmHg in systolic blood pressure in women (95% CI –4.0 to –0.05, P = 0.045).

Conclusions Few associations were observed between change in different physical activity domains and cardiovascular disease risk factors in this trial cohort. Cardiovascular disease risk reduction appeared to be driven largely by factors other than changes in self-reported physical activity in the first year following diagnosis.

Diabet. Med. 30, 233-238 (2013)

Introduction

Following diagnosis of Type 2 diabetes, patients are advised about the importance of physical activity for weight loss and for controlling blood glucose, blood pressure and blood lipid levels. There is good evidence that exercise training has a beneficial effect on cardiovascular risk factors in people with established diabetes [1–5]. Most research on physical activity recommendations in diabetes focuses on individuals with clinically diagnosed and/or well-established disease. Given that population screening for diabetes has been recommended by several national organizations and the National Health Service (NHS) currently includes assessment of risk of diabetes in its

Correspondence to: Rebecca Simmons. E-mail: rebecca.simmons@mrc-epid.cam.ac.uk Health Checks programme [6], more individuals will be found earlier in the disease trajectory, where there is little current evidence for physical activity recommendations. Indeed, the National Institute for Health and Clinical Excellence (NICE) do not offer explicit guidance on exercise type, frequency or duration in Type 2 diabetes. Furthering our understanding of cardiovascular disease risk reduction in individuals with screendetected diabetes will thus allow improvement in diabetes care and appropriate targeting of resources.

ADDITION-Cambridge is a primary care-based study of screening for Type 2 diabetes followed by a pragmatic cluster randomized controlled trial comparing intensive multifactorial treatment with routine care in patients with screen-detected diabetes. We aimed (1) to describe change in different physical activity domains and modelled cardiovascular disease risk over 1 year and (2) to explore whether change in physical activity was associated with a reduction in modelled cardiovascular disease risk in this screen-detected population.

Patients and methods

The design and rationale for ADDITION-Cambridge have previously been reported [7]. In brief, 49 general practice surgeries in the Eastern region of England recruited patients through a stepwise screening programme. Individuals were eligible for screening if they were registered with one of the participating general practices, were aged 40-69 years, not known to have diabetes and with a diabetes risk score of > 0.17 (corresponding to the top 25% of the population distribution [8]). Exclusion criteria included pregnancy, lactation, an illness with a life expectancy of less than 12 months or a psychiatric disorder that might invalidate informed consent. Thus, 33 539 eligible participants were invited to take part in the screening programme [9]. World Health Organization (WHO) criteria were used to diagnose diabetes [10]. In total, 867 individuals with screendetected diabetes agreed to participate and provided written informed consent. Ethical approval was granted by the Eastern Multi-Regional Ethics Committee (reference 02/5/54).

Participants were managed according to the treatment regimen to which their practice was allocated: intensive treatment or routine care. The intensification of diabetes management was achieved through the addition of a number of features to existing diabetes care [7,11], alongside lifestyle advice concerning diet, physical activity and tobacco consumption, and a stepwise target-led drug treatment regime to reduce hyperglycaemia, blood pressure, hyperlipidaemia and microalbuminuria. Routine care practices followed current UK national guidelines for diabetes management [12–14].

Measurement and outcomes

Baseline and 1-year health assessments included physiological and anthropometric measurements, venesection and the completion of questionnaires [7]. Modelled 10-year risk of cardiovascular disease was calculated using the UK Prospective Diabetes Study (UKPDS) risk engine (version 3.0) [15]. Data on physical activity were collected using the European Prospective Investigation into Cancer (EPIC)-Norfolk physical activity questionnaire (EPAQ-2 version 4.0), which has previously been validated using objective heart rate monitoring [16]. This selfreport questionnaire is designed to measure domain-specific physical activity in the past year and asks about physical activity patterns in and around the house, activity at work, travel to work and recreational physical activity. Vigorous physical activity was calculated using duration, type and frequency of exercise collected in the recreational physical activity section.

Statistical analyses

Baseline and follow-up characteristics were summarized separately in men and women. Multiple linear regression models were used to describe the association between change in physical activity and cardiovascular risk factors and modelled cardiovascular risk at 1 year; results are reported as standardised β -coefficients. All models were run separately by sex and adjusted for baseline physical activity behaviour, age, randomization group, change in smoking status, change in calorie intake and relevant medication. Data were analysed using SPSS (version 18.0; SPSS Inc., Chicago, IL, USA).

Results

Baseline characteristics of ADDITION-Cambridge participants with complete data for baseline and follow-up (n = 736) are presented separately by gender in Table 1. Non-attenders to the follow-up health assessment reported lower levels of baseline recreational physical activity and were more likely to have experienced a previous heart attack or stroke than attenders. For all other characteristics there were no significant differences between attenders and non-attenders (data not shown).

Change in cardiovascular disease risk factors, modelled cardiovascular disease risk and physical activity

As shown in Table 1, for both men and women, there were significant reductions in anthropometric and biochemical risk factors, alongside increases in the prescription of cardio-protective medication and improvements in calorie intake, alcohol consumption and smoking status.

In women, there was no change in home, work or recreational physical activity between baseline and follow-up. There was a small non-significant increase in vigorous physical activity (0.08 h/week). For men, there were small non-significant increases in recreational (3.9 metabolic equivalent h/week) and vigorous physical activity (0.18 h/week). Although mean change in self-reported physical activity from baseline to follow-up was non-significant, the standard deviations for physical activity change were very large, indicating that some individuals reported large increases or reductions in their physical activity behaviour.

Association between change in physical activity, cardiovascular disease risk factors and modelled cardiovascular disease risk

As shown in Table 2, for men, an increase in recreational physical activity over 1 year was independently associated with a reduction in HbA_{1c} [β (95% CI); -0.093 (-0.17 to -0.014), P = 0.021], while in women an increase in recreational physical activity was independently associated with a reduction in systolic blood pressure [β (95% CI); -2.32 (-4.60 to -0.051, P = 0.045]. There were no significant associations between change in any other physical activity domain, cardiovascular disease risk factors and modelled cardiovascular disease risk at 1 year. Although the β -coefficients were largely in the expected

20
2
Ш
11
<u> </u>
đ
1
Ň
ПС
6
r.
сa
-ř-
÷
φ
ц
0
ŭ
eli
1S(
ĥ
Ę
6
ta
da
ē
et
d
E
0
2
Et.
- M
s
nt
)a
÷≓
τi.
ar
ñ,
e.
ಕೆ
.1
qu
an
Ŭ
÷
1
Ы
E
D
D
A
μ
0
CS
sti
Ξ
ïte
ac
ar
Ä
\circ
5
Ð
9
a

nballow eq. k ballow eq. k <th< th=""><th></th><th>Men (n</th><th>= 453)</th><th></th><th></th><th>Women</th><th>(n = 283)</th><th></th><th></th></th<>		Men (n	= 453)			Women	(n = 283)		
der yets: 453 63 753 - - 283 63 63 - - - 283 53 -		и	Baseline	Follow-up	<i>P</i> -value*	и	Baseline	Follow-up	<i>P</i> -value*
Answer untrate	Age, years	453	60.3 (7.5)	I	I	283	62.3 (6.3)	I	I
	Age misned full-time concation, 70 × 16 verse	453	45.7	I	I	783	52.0	I	I
r so parts 12.4 9.5 9.5 r finder, "S 13 years 12.4 9.5 - - - 23 9.5 - - - - 35 35 35 35 0.13 9.5 - - - - 23 9.5 - - - - 35 35 35 35 0.13 9.5 0.13 9.5 - - - - - 23 9.5 3.6 0.03 35 3.6 0.03 3.6	10 June 10		4. CF			004	0.40		
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	10-10 years		42.4				00.0 0		
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	> 18 years		12.4				9.3		
White 432 27.6 - - 283 35.8 - - - - - 133 55.8 - - - - - 133 35.8 - </td <td>Ethnicity, %</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Ethnicity, %								
	White	452	97.6	Ι		283	95.8	Ι	
	Asian		2.2				3.5		
	Previous heart attack, % yes	452	10.9	11.4	0.65	283	2.5	3.6	0.56
	Previous stoke, % yes	452	3.8	4.6	0.32	283	3.9	5.5	0.13
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Weight, kg	448	98.6 (17.3)	95.4 (16.8)	< 0.001	282	88.2 (15.9)	84.0 (15.8)	< 0.001
	Waist circumference, cm	451	114.2 (13.0)	111.4 (12.9)	< 0.001	282	107.5 (13.0)	103.9 (13.0)	< 0.001
$ \begin{array}{cccccc} A \mbox{coek} & 438 & 10.0 (12.3) & 8.9 (11.3) & 0.003 & 269 & 3.6 (6.1) & 3.1 (5.1) & < 0.011 \\ solving starts, $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$	BMI, kg/m ²	448	32.6 (5.2)	31.7(5.1)	< 0.001	281	34.5 (5.9)	33.0 (5.9)	< 0.001
	Alcohol, units/week	438	10.0 (12.3)	8.9 (11.3)	0.003	269	3.6(6.1)	3.1(5.1)	< 0.001
$ \begin{array}{ccccc} \text{Non-simoker/former} & 445 & 810 & 82.7 & 0.23 & 279 & 86.2 & 88.9 & 0.01 \\ \text{Current moder} & 101 & 17.3 & 11.1 & $	Smoking status, %								
$ \begin{array}{ccccc} \mbox{Current smoker} & 190 & 17.3 \\ \mbox{Tard energy insides, kal/day} & 440 & 2014.8 (708.6) & 1731.4 (527.9) & < 0.01 & 276 & 1797.7 (52.5.5) & [631.7 (603.8) & < 0.001 \\ \mbox{Elemental physical activity} & 440 & 2014.8 (708.6) & 1731.4 (527.9) & < 0.01 & 276 & 1797.7 (52.5.5) & [631.7 (603.8) & < 0.001 \\ \mbox{Elemental physical activity} & 433 & 297 (28.6) & 31.5 (25.7) & 0.15 & 269 & 599 (30.4) & 599 (33.0) & 0.97 \\ \mbox{Work (MET h/week)} & 241 & 0.33 (40.2) & 0.36 & 102.3 (59.2) & 0.055 & 756 & 62.5 (41.5) & 0.64 (49.1) & 0.34 \\ \mbox{Work (MET h/week)} & 441 & 0.94 (1.7) & 0.39 (1.6) & 0.080 & 280 & 0.24 (0.7) & 0.24 (0.9) & 0.05 \\ \mbox{Work (MET h/week)} & 447 & 51.9 & 64.4 & -0.001 & 282 & 20.1 & 52.8 & -0.001 \\ \mbox{Ugrows (h/week)} & 447 & 51.9 & 64.4 & -0.001 & 282 & 20.1 & 52.8 & -0.001 \\ \mbox{Lipid lowering medication} & 447 & 51.9 & 64.4 & -0.001 & 282 & 61.1 & 69.9 & 0.001 \\ \mbox{Lipid lowering medication} & 441 & 51.1 & 14.3 (19.9) & 133.3 (18.2) & < 0.001 & 282 & 61.1 & 69.9 & 0.001 \\ \mbox{Lipid lowering medication} & 440 & 57 (1.3) & 64.010 & 280 & 135.5 (19.8) & 132.9 (18.7) & < 0.001 \\ \mbox{Systolic blood pressure, mmHg} & 441 & 0.31 (0.1) & < 0.001 & 280 & 135.5 (19.8) & 132.9 (18.7) & < 0.001 \\ \mbox{HA}, & & & & & & & & & & & & & & & & & & &$	Non-smoker/former	445	81.0	82.7	0.23	279	86.2	88.9	0.01
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Current smoker		19.0	17.3			13.8	11.1	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Total energy intake keal/day	440	2014 8 (708 6)	1731 4 (577 9)	~ 0.001	276	1797 7 1625 51	1631 7 (603 8)	~ 0.001
$ \begin{array}{cccc} \mbox{the MET} hvee(h) & 43 & 297 (28.6) & 31.5 (25.7) & 0.15 & 269 & 599 (30.4) & 599 (33.0) & 0.97 \\ \mbox{Work (MET} hvee(h) & 413 & 297 (28.6) & 102.3 (59.2) & 0.55 & 76 & 6.25 (41.5) & 664 (49.1) & 0.34 \\ \mbox{Work (MET} hvee(h) & 413 & 33.9 (40.2) & 37.8 (40.9) & 0.058 & 271 & 22.3 (30.4) & 0.04 (25.6) & 0.089 \\ \mbox{Vignous (hvee(h)) } & 47 & 0.39 (11.7) & 0.39 (1.6) & 0.080 & 280 & 0.24 (0.7) & 0.32 (0.8) & 0.081 \\ \mbox{Vignous (hvee(h)) } & 47 & 25.4 & 57.1 & 0.011 & 282 & 20.1 & 52.3 (0.6) & 0.081 \\ \mbox{Lipd lowering medication} & 47 & 25.4 & 57.1 & 0.001 & 282 & 20.1 & 52.8 & 0.001 \\ \mbox{Lipd lowering medication} & 47 & 25.4 & 57.1 & 0.001 & 282 & 61.1 & 6.9 & 9.0 & 0.001 \\ \mbox{Lipd lowering medication} & 47 & 51.9 & 44 (1.0) & <0.001 & 282 & 61.1 & 6.9 & 9.0 & 0.01 \\ \mbox{Loces lowering medication} & 43 & 5.3 (1.1) & 4.4 (1.0) & <0.001 & 282 & 61.1 & 6.9 & 9.0 & 0.01 \\ \mbox{Loces lowering medication} & 44 & 57.1 & 0.31 (0.1) & 280 & 139.5 (19.8) & 132.9 (18.7) & 0.001 \\ \mbox{Loces lowering medication} & 44 & 57 (0.8) & 6.001 & 269 & 55 (0.9) & 6.001 \\ \mbox{Loces lowering medication} & 44 & 0 & 57 (VA)5 & 6.001 & 269 & 55 (1.9) & 6.001 \\ \mbox{Loces lowering medication} & 44 & 0 & 57 (0.1) & 0.31 (0.1) & 0.31 (0.1) & 269 & 55 (0.9) & 6.001 \\ \mbox{Loces lowering medicated} & rest & 42 & 0.36 (0.1) & 0.31 (0.1) & 269 & 72 (1.6) & 6.5 (0.3) & 6.001 \\ \mbox{Loces lowering medicated} & rest & 42 & 0.36 (0.1) & 0.31 (0.1) & 269 & 72 (1.6) & 6.5 (0.8) & 6.001 \\ \mbox{Loces lowering medicated} & rest & 42 & 0.36 (0.1) & 0.31 (0.1) & 269 & 72 (1.6) & 6.5 (0.8) & 6.001 \\ \mbox{Loces lowering medicated} & rest & r$	Salf-renorted physical activity	-			10000) Ì		(0.000)	10000
$ \begin{array}{ccccc} \mbox{Work} (MET hweek) & \mbox{Her} hweek) & \mbox{He} hweek) & \mbox{H} hw$	JULTIC ATT L ZEELAND	<i>cc1</i>		21 5 7 2 7	0.15	070	50 0 / 20 4/	20 0 122 01	10.0
Work (MET b/week)† 204 104.0 (55.6) 102.3 (59.2) 0.55 76 62.5 (41.5) 66.4 (49.1) 0.34 Recreational (MET h/week)† 413 339 (40.2) 37.3 (40.9) 0.055 271 20.4 (0.7) 0.32 (0.8) 0.03 Prescribed medication 471 0.41 (1.7) 0.39 (1.6) 0.085 221 22.3 (30.4) 20.4 (22.6) 0.03 Prescribed medication 477 51.9 0.39 (1.6) 0.085 221 22.3 (30.4) 20.4 (22.6) 0.03 Choose lowering medication 477 51.9 64.4 <0.01	Home (MET n/week)	400	(9.07) (20.0)	(/.07) 0.10	CT.U	697	(4.06) 2.20	(0.55) 6.65	1.97
Recretional (MET h/week) 413 33.9 (40.2) 37.8 (40.9) 0.055 271 23.3 (30.4) 20.4 (22.6) 0.31 Vigrous (h/week) 451 0.41 (1.7) 0.39 (1.6) 0.080 280 0.24 (0.7) 0.32 (0.8) 0.098 Prescribed medication, % yes 47 2.5 5.7.1 <0.001	Work (MET h/week)†	204	104.0(55.6)	102.3(59.2)	0.55	76	62.5(41.5)	66.4 (49.1)	0.34
Vigorous (h/week) 451 0.41 (1.7) 0.59 (1.6) 0.080 280 0.24 (0.7) 0.32 (0.8) 0.098 Prescribed medication, % yes 47 25.4 57.1 0.39 (1.6) 0.080 280 0.24 (0.7) 0.32 (0.8) 0.098 Prescribed medication 47 25.4 57.1 < 0.001 282 20.1 52.8 < 0.001 Anti-hypertensive medication 47 51.9 64.4 < 0.001 282 61.1 69.9 < 0.001 Anti-hypertensive medication 47 51.9 64.4 < 0.001 282 61.1 69.9 < 0.001 Anti-hypertensive medication 47 51.9 64.4 < 0.001 282 61.1 69.9 < 0.001 Anti-hypertensive medication 440 57 (1/VA)\$ 48 (N/A)\$ < 0.001 289 $< 5.0(0.9)$ < 0.001 BA ₁₄ 57 0.36 (0.1) 0.31 (0.1) < 0.001 289 $< 5.0(0.9)$ < 0.001 Modelled 10-year cartiovascular d	Recreational (MET h/week)	413	33.9 (40.2)	37.8 (40.9)	0.055	271	22.3 (30.4)	20.4 (22.6)	0.31
$ \begin{array}{ccccc} \mbox{Prescribed medication} & 47 & 254 & 57.1 & < 0.001 & 282 & 20.1 & 5.28 & < 0.001 \\ \mbox{Lipid lowering medication} & - & - & - & - & - & - & - & - & - & $	Vigorous (h/week)	451	0.41 (1.7)	0.59(1.6)	0.080	280	0.24(0.7)	0.32(0.8)	0.098
Lipid lowering medication 447 25.4 57.1 < 0.001 282 20.1 52.8 < 0.001 Auri-bypertensive medication $ -$ 28.7 $-$ Auri-bypertensive medication 447 51.9 64.4 < 0.001 282 61.1 69.9 < 0.001 Cardiovascular risk factors 433 5.3 (1.1) 4.4 (1.0) < 0.001 282 61.1 69.9 < 0.001 Cardiovascular risk factors 441 5.3 (1.1) 4.4 (1.0) < 0.001 282 $5.1.1$ $6.9.9$ < 0.001 Total cholesterol, mmol/ 440 5.7 (N/A) 48 (N/A) < 0.001 269 5.5 (N/A) < 0.001 Total cholesterol, mmol/mol 7.4 (1.8) 6.5 (0.9) < 0.001 269 5.6 (1.2) $4.7 (0.8) < 0.001 Total cholesterol 7.2 (1.6) 6.5 (0.9) < 0.001 269 5.6 (0.0) < 0.001 $	Prescribed medication, % yes								
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Lipid lowering medication	447	25.4	57.1	< 0.001	282	20.1	52.8	< 0.001
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Glucose lowering medication	Ι	I	31.1		Ι	I	28.7	
Cardiovascular risk factorsTotal cholesterol, mmol/1 443 $5.3(1.1)$ $4.4(1.0)$ <0.001 274 $5.6(1.2)$ $4.7(0.8)$ <0.001 Systolic blood pressure, mmHg 451 $143.2(19.9)$ $113.3(18.2)$ <0.001 209 $5.6(1.2)$ $4.7(0.8)$ <0.001 BhA _{1c} , mmol/mol 440 $5.7(N/A)$ $48(N/A)$ <0.001 269 $5.6(1.2)$ $4.7(0.8)$ <0.001 HbA _{1c} , M 440 $5.7(N/A)$ $48(N/A)$ <0.001 269 $5.5(N/A)$ $48(N/A)<0.001HbA1c, M0.36(0.1)0.31(0.1)0.31(0.1)2695.7(N/A)48(N/A)<0.001Modelled 10-year cardiovascular disease risk‡4230.36(0.1)0.31(0.1)<0.0012695.5(0.8)<0.001All values are means (SD) unless otherwise indicated.McNemar's test for caregorical variables and paired t-test for continuous variables.fincluding only those participants who had a job at baseline and 1 year.Calculated using the UK Prospective Diabetes Study (URDDS) risk engine (version 3), excluding participants who experienced a previous heart attack or stroke.fincluding only those participants who ad a job at baseline and 1 year.fincluding only those participants who experienced a previous heart attack or stroke.fit is sto possible to calculate International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) values for low HbAlc values.fit is sto possible to calculate International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) values for low HbA$	Anti-hypertensive medication	447	51.9	64.4	< 0.001	282	61.1	69.9	< 0.001
Total cholesterol, mmol/14435.3 (1.1)4.4 (1.0)< 0.001 274 5.6 (1.2) 4.7 (0.8)< 0.001Systolic blood pressure, mmHg451143.2 (19.9)138.3 (18.2)< 0.001	Cardiovascular risk factors								
Systolic blood pressure, mmHg451143.2 (19.9)138.3 (18.2)< 0.001280139.5 (19.8)132.9 (18.7)< 0.001 HA_{1c} , mmol/mol 440 57 (N/A)§ 48 (N/A)§< 0.001	Total cholesterol, mmol/l	443	5.3(1.1)	4.4(1.0)	< 0.001	274	5.6(1.2)	4.7 (0.8)	< 0.001
HbA1c, mmol/mol440 $57 (N/A)$ 48 (N/A) $66.5 (0.9)$ $55 (N/A)$ $48 (N/A)$ 80.001 HbA1c, %440 $7.4 (1.8)$ $6.5 (0.9)$ 6.001 269 $55 (N/A)$ $48 (N/A)$ < 0.001 Modelled 10-year cardiovascular disease risk420 $7.4 (1.8)$ $6.5 (0.9)$ < 0.001 269 $7.2 (1.6)$ $6.5 (0.8)$ < 0.001 All values are means (SD) unless otherwise indicated. $*McNemar's test for categorical variables and paired t-test for continuous variables.< 0.0012550.23 (0.1)0.18 (0.09)< 0.001All values are means (SD) unless otherwise indicated.< 0.36 (0.1)0.31 (0.1)< 0.0012550.23 (0.1)0.18 (0.09)< 0.001All values are means (SD) unless otherwise indicated.< 0.36 (0.1)0.31 (0.1)< 0.0012550.23 (0.1)0.18 (0.09)< 0.001All values are means (SD) unless otherwise indicated.< 0.36 (0.1)0.31 (0.1)< 0.0012550.23 (0.1)0.18 (0.09)< 0.001All values are means (SD) unless otherwise indicated.< 0.0012550.23 (0.1)0.18 (0.09)< 0.001All values are means (SD) unless otherwise indicated.< 0.0012550.23 (0.1)< 0.001< 0.001< 0.001< 0.001< 0.001< 0.001< 0.001< 0.001< 0.001< 0.001< 0.001< 0.001< 0.001< 0.001< 0.001< 0.001< 0.001< 0.001< 0.001$	Systolic blood pressure, mmHg	451	143.2 (19.9)	138.3(18.2)	< 0.001	280	139.5 (19.8)	132.9 (18.7)	< 0.001
HbA1c, % 440 $7.4 (1.8)$ $6.5 (0.9)$ < 0.001 269 $7.2 (1.6)$ $6.5 (0.8)$ < 0.001 Modelled 10-year cardiovascular disease risk; 423 $0.36 (0.1)$ $0.31 (0.1)$ < 0.001 255 $0.23 (0.1)$ $0.18 (0.09)$ < 0.001 All values are means (SD) unless otherwise indicated.*McNemar's test for categorical variables and paired <i>t</i> -test for continuous variables.†Including only those participants who had a job at baseline and 1 year.\$Calculated using the UK Prospective Diabetes Study (UKPDS) risk engine (version 3), excluding participants who experienced a previous heart attack or stroke.\$It is not possible to calculate International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) values for low HbA1c values.The sample size was at least 413 for men and 255 for women for all variables, with the exception of work (self-reported physical activity) (men = 204; women = 76)MFT mean-bulkMFT mean-bulk	HbA _{1c} , mmol/mol	440	57 (N/A)§	48 (N/A)§	< 0.001	269	55 (N/A)§	48 (N∕A)§	< 0.001
Modelled 10-year cardiovascular disease risk;4230.36 (0.1)0.31 (0.1)< 0.0012550.23 (0.1)< 0.09)< 0.001All values are means (SD) unless otherwise indicated.*McNemar's test for categorical variables and paired <i>t</i> -test for continuous variables.†Including only those participants who had a job at baseline and 1 year.\$Calculated using the UK Prospective Diabetes Study (UKPDS) risk engine (version 3), excluding participants who experienced a previous heart attack or stroke.\$It is not possible to calculate International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) values for low HbA1c values.The sample size wat at ast 413 for men and 255 for women for all variables, with the exception of work (self-reported physical activity) (men = 204; women = 76)MFT meanbulke and NA nor avoid has	HbA_{1c} , %	440	7.4(1.8)	6.5(0.9)	< 0.001	269	7.2(1.6)	6.5(0.8)	< 0.001
All values are means (SD) unless otherwise indicated. *McNemar's test for categorical variables and paired <i>t</i> -test for continuous variables. †Including only those participants who had a job at baseline and 1 year. ‡Calculated using the UK Prospective Diabetes Study (UKPDS) risk engine (version 3), excluding participants who experienced a previous heart attack or stroke. §It is not possible to calculate International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) values for low HbA1c values. The sample size was at least 413 for men and 255 for women for all variables, with the exception of work (self-reported physical activity) (men = 204; women = 76)	Modelled 10-year cardiovascular disease risk‡	423	0.36(0.1)	0.31(0.1)	< 0.001	255	0.23(0.1)	0.18(0.09)	< 0.001
*McNemar's test for categorical variables and paired <i>t</i> -test for continuous variables. *McNemar's test for categorical variables and paired <i>t</i> -test for continuous variables. †Including only those participants who had a job abseline and 1 year. ‡Calculated using the UK Prospective Diabetes Study (UKPDS) risk engine (version 3), excluding participants who experienced a previous heart attack or stroke. \$It is not possible to calculate International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) values for low HbA1c values. The sample size was at least 413 for men and 255 for women for all variables, with the exception of work (self-reported physical activity) (men = 204; women = 76) MFT mean-balic activity and activity and activity and activity and activity (men = 204; women = 76)	All values are means (SD) unless otherwise indicate	Ч.							
†Including only those participants who had a job at baseline and 1 year. ‡Calculated using the UK Prospective Diabetes Study (UKPDS) risk engine (version 3), excluding participants who experienced a previous heart attack or stroke. ‡Calculated using the UK Prospective Diabetes Study (UKPDS) risk engine (version 3), excluding participants who experienced a previous heart attack or stroke. ‡This not possible to calculate International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) values for low HbA1c values. The sample size was a least 413 for men and 255 for women for all variables, with the exception of work (self-reported physical activity) (men = 204; women = 76).	*McNemar's test for categorical variables and paire	ed t-test for	continuous variables.						
Calculated using the UK Prospective Diabetes Study (UKPDS) risk engine (version 3), excluding participants who experienced a previous heart attack or stroke. It is not possible to calculate International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) values for low HbA1c values. The sample size was at least 413 for men and 255 for women for all variables, with the exception of work (self-reported physical activity) (men = 204; women = 76)	†Including only those participants who had a job at	t baseline a	nd 1 year.						
It is not possible to calculate International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) values for low HbA1c values. The sample size was at least 413 for men and 255 for women for all variables, with the exception of work (self-reported physical activity) (men = 204; women = 76) MET metabolic antivolute MVA new availables	Calculated using the UK Prospective Diabetes Stuc	ly (UKPDS)	risk engine (version 3), excluding participan	ts who experien	ced a previo	us heart attack or sti	roke.	
The sample size was at least 413 for men and 255 for women for all variables, with the exception of work (self-reported physical activity) (men = 204 ; women = 76)	It is not possible to calculate International Federat	ion of Clin	ical Chemistry and Lal	ooratory Medicine (IFG	CC) values for lo	w HbA1c	alues.		
MET matchaite antitudents is a statistical and the statistical at the statistical	The sample size was at least 413 for men and 255	for women	for all variables, with	the excention of work	(self-renorted n	usical activ	itv) (men = 2.04 : wor	nen = 76)	
	MET matchelic aminulant. N/A not available		<i>(</i>		T J		he and an and the	/	

		Standard	dized B-coefficient	*									
Dutcome		Total choleste	rol 95% CI	P-v	Systolic blood alue pressure	95% CI	P-value	HbA_{1c}	95% CI	P-value	Modelled cardiovascular disease risk§	95% CI	P-value
home physical activ MET h/week) work	ity Crude Adjustec Crude	-0.042 1† -0.030 -0.17	-0.15 to 0.(-0.11 to 0.(-0.42 to 0.0	063 0.4 056 0.4 075 0.1	3 -1.42 9 -1.50 7 0.44	-3.63 to 0.98 -3.41 to 0.41 -5.26 to 6.14	$\begin{array}{c} 0.21 \\ 0.12 \\ 0.88 \end{array}$	-0.044 -0.030 -0.026	-0.14 to 0.049 -0.11 to 0.048 -0.23 to 0.18	0.35 0.45 0.80	-0.004 -0.003 -0.006	-0.014 to 0.006 -0.010 to 0.003 -0.023 to 0.011	$\begin{array}{c} 0.39\\ 0.33\\ 0.48\end{array}$
physical activity‡ MET h/week) recreational physica	Adjustec I Crude	d† −0.083 −0.009	-0.28 to 0. -0.03 to 0.1	12 0.4 12 0.8	$\begin{array}{ccc} 1 & 1.52 \\ 9 & -2.01 \end{array}$	-3.58 to 6.62 -4.69 to 0.68	$0.55 \\ 0.14$	0.053 0.027	-0.15 to 0.26 -0.083 to 0.14	$0.61 \\ 0.93$	0.003 - 0.006	-0.007 to 0.012 -0.018 to 0.006	0.56 0.29
activity MET h/week) vigorous	Adjustec Crude	d† −0.029 −0.14	-0.13 to 0.0 -0.39 to 0.1	076 0.5 10 0.2	9 -2.32 5 -4.39	-4.60 to -0.05 -9.44 to 0.66	: 0.045 0.088	0.022 0.020	-0.072 to 0.12 -0.19 to 0.24	0.65 0.85	-0.005 -0.016	-0.013 to 0.003 -0.039 to 0.007	$0.22 \\ 0.16$
physical activity 1/week)	Adjustec	d† −0.15	-0.34 to 0.0	0.1 0.1	4 -2.49	-6.83 to 1.85	0.26	0.023	-0.16 to 0.21	0.80	-0.003	-0.018 to 0.012	0.71
utcome		T otal cholesterol	95% CI	P-valu	Systolic blood e pressure	95% CI	P-value	HbA _{1c}	95% CI	<i>P</i> -value	Modelled cardiovascular disease risk§	95% CI	<i>P</i> -value
home physical	Crude	-0.071	-0.17 to 0.029	0.16	-0.52	-2.29 to 1.26	0.57	-0.004	-0.094 to 0.086	0.93	-0.001	-0.013 to 0.011	0.87
activity AET h/week) work	Adjusted† Crude	-0.021 -0.055	-0.098 to 0.056 -0.19 to 0.077	0.60	-0.84 -2.55	-2.34 to 0.66 -4.96 to -0.14	0.27 0.038	0.009	-0.075 to 0.093 -0.24 to 0.008	$\begin{array}{c} 0.83 \\ 0.067 \end{array}$	-0.003 -0.012	-0.010 to 0.005 -0.026 to 0.003	$0.48 \\ 0.12$
bhysical activity ‡ ^c AET h/week) recreational	Adjusted† Crude	-0.001 0.001	-0.093 to 0.090 -0.089 to 0.091	0.98	$-1.21 \\ 0.16$	-3.17 to 0.76 -1.50 to 1.82	0.23	-0.079	-0.19 to 0.037 -0.17 to 0.001	$0.18 \\ 0.052$	-0.004 -0.012	-0.013 to 0.005 -0.12 to 0.014	0.40 0.028
ohysical activity AET h/week) vigorous	Adjusted† Crude	$0.012 \\ 0.069$	-0.058 to 0.081 -0.008 to 0.15	0.74 0.079	0.79 0.90	-0.62 to 2.20 -0.48 to 2.29	0.27	-0.093	-0.17 to -0.014 -0.11 to 0.036	$0.021 \\ 0.33$	-0.006 0.003	-0.013 to 0.001 -0.006 to 0.012	$0.11 \\ 0.53$
physical activity 1/week)	Adjusted†	0.029	-0.031 to 0.089	0.35	0.56	-0.60 to 1.73	0.34	-0.033	-0.099 to 0.033	0.33	0.001	-0.005 to 0.007	0.67

direction of effect, the coefficients were small and not statistically significant.

Discussion

There was no change in self-reported physical activity over 12 months in a population of patients newly diagnosed with Type 2 diabetes in the East of England. There were significant decreases in cardiovascular disease risk factors and modelled cardiovascular disease risk. Increases in recreational physical activity were associated with a significant reduction in HbA_{1c} in men and systolic blood pressure in women. Changes in other physical activity domains were not associated with a reduction in modelled cardiovascular disease risk. Our finding suggests that more attention may need to be paid to the promotion of physical activity following diagnosis of diabetes. Reduction in modelled cardiovascular disease risk may be driven by factors other than self-reported physical activity in this screen-detected cohort. These include changes in medication and dietary behaviour [17].

Similar reductions in cardiovascular disease risk factors have been seen in patients with diabetes enrolled in lifestyle interventions. In the Italian Diabetes and Exercise Study (IDES) study [4], 606 sedentary individuals with diabetes and the metabolic syndrome were randomized to twice-weekly supervised aerobic and resistance training and structured exercise counselling, or counselling alone (control group) for 12 months. Increases in physical activity were associated with significant improvements in fitness, HbA1c, blood pressure, cholesterol, waist circumference and modelled coronary heart disease risk. Contrary to our findings, self-reported physical activity remained a significant driver of cardiovascular disease risk reduction in this cohort even after adjustment for statin treatment (the only medication that changed significantly in both groups). In the Early Activity in Diabetes (Early ACTID) trial, 593 recently diagnosed patients with diabetes were randomized to (1) usual care (control), (2) an intensive diet intervention or (3) an intensive diet intervention plus a pedometer-based activity programme [17]. After 12 months, there were significant improvements in glycaemic control, insulin resistance and bodyweight in both intervention groups compared to the control; however, the addition of the activity intervention conferred no extra benefit. Other studies examining behavioural change in patients with Type 2 diabetes tend to be small, of shorter duration and focus on individuals later in the disease trajectory.

It is possible that physical activity did not significantly increase over 1 year in the ADDITION-Cambridge cohort because of the nature of the physical activity intervention. Participants in the intensive treatment group were advised to increase their physical activity to reach a goal of 35 min of brisk walking every day. However, other physical activity studies in patients with diabetes have set more challenging goals; for example, a minimum of 150 min/week of progressive mixed training [4], as well as offering a higher number of counselling sessions [3]. Measures of change in physical activity were calculated from a self-report questionnaire, which may have been subject to error and bias. Physical activity might have increased a little after diagnosis, but changes over the time period covered by the EPIC-Norfolk physical activity questionnaire were not apparent. We may not therefore have captured the full extent of physical activity behaviour change. Finally, physical activity behaviour may not be a driver of reduction in risk factors in screen-detected individuals, who are earlier in the diabetes disease trajectory and for whom the initiation of a medication regime may be the biggest change in the first year following diagnosis.

Strengths and limitations

Anthropometric and clinical measurements were undertaken by trained staff following standard operating procedures. We adjusted for both change in medication use and change in total calorie intake between baseline and 1 year, which might have impacted on cardiovascular disease risk at follow-up, and which other studies have not adjusted for [3,4]. The study is of larger size and longer duration than many studies in patients with diabetes, which are typically limited to less than 1 year. Extrapolation of our results to more deprived and ethnically diverse settings may be limited in light of the non-random recruitment of general practices from a single geographical region (Eastern England). We conducted multiple significance tests (> 20) between change in physical activity and cardiovascular disease risk factors which may have led to an increased risk of Type 1 errors. It is therefore unclear whether the few significant observations represent real or chance associations.

Conclusions

Few associations were observed between change in physical activity, cardiovascular disease risk factors and modelled cardiovascular disease risk over 12 months in ADDITION-Cambridge. The observed reduction in cardiovascular disease risk factors may have been driven by factors other than physical activity in the first year following diagnosis. Physical activity has benefits beyond effects on cardiovascular disease risk factors at 1 year and therefore merits promotion in patients with diabetes.

Funding sources

None.

Competing interests

None declared.

Acknowledgements

ADDITION-Cambridge was supported by the Wellcome Trust (grant reference no. G061895), the Medical Research

Council (grant reference no. G0001164), the NIHR Health Technology Assessment Programme (grant reference no. 08/116/300), National Health Service R&D support funding (including the Primary Care Research and Diabetes Research Networks) and the National Institute for Health Research. SJG receives support from the Department of Health NIHR Programme Grant funding scheme (RP-PG-0606-1259). The views expressed in this publication are those of the authors and not necessarily those of the UK Department of Health. Bio-Rad provided equipment for HbA_{1c} testing during the screening phase. We thank Dr Marcel Adriaanse (VU University, Amsterdam) for his helpful comments on the manuscript.

We are grateful to the ADDITION-Cambridge independent trial steering committee [Nigel Stott (Chair), John Weinman, Richard Himsworth and Paul Little]. Aside from the authors, the ADDITION-Cambridge study team has included Rebecca Abbott, Amanda Adler, Judith Argles, Gisela Baker, Rebecca Bale, Roslyn Barling, Daniel Barnes, Mark Betts, Sue Boase, Sandra Bovan, Ryan Butler, Parinya Chamnan, Sean Dinneen, Pesheya Doubleday, Sue Emms, Mark Evans, Tom Fanshawe, Francis Finucane, Philippa Gash, Julie Grant, Wendy Hardeman, Robert Henderson, Susie Hennings, Muriel Hood, Garry King, Georgina Lewis, Christine May Hall, Joanna Mitchell, Richard Parker, Nicola Popplewell, Emanuella De Lucia Rolfe, Lincoln Sargeant, Megan Smith, Stephen Sutton, Liz White and Fiona Whittle. We thank the Cambridge University Hospitals NHS Foundation Trust Department of Clinical Biochemistry and the NIHR Cambridge Biomedical Research Centre, Core Biochemical Assay Laboratory for carrying out the biochemical assays, and the following groups within the MRC Epidemiology Unit: data management (Adam Dickinson), information technology (Iain Morrison), technical (Matt Sims) and field epidemiology (Paul Roberts, Kim Mwanza and James Sylvester).

References

- 1 Snowling NJ, Hopkins WG. Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta-analysis. *Diabetes Care* 2006; **29**: 2518–2527.
- 2 Norris SL, Zhang X, Avenell A, Gregg E, Bowman B, Serdula M et al. Long-term effectiveness of lifestyle and behavioral weight loss interventions in adults with type 2 diabetes: a meta-analysis. Am J Med 2004; 117: 762–774.
- 3 Look AHEAD research group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: 4-year results of the Look AHEAD trial. *Arch Intern Med* 2010; **170**: 1566–1575.

- 4 Balducci S, Zanuso S, Nicolucci A, De Feo P, Cavallo S, Cardelli P et al. Effect of an intensive exercise intervention strategy on modifiable cardiovascular risk factors in subjects with type 2 diabetes mellitus: a randomized controlled trial: the Italian Diabetes and Exercise Study (IDES). Arch Intern Med 2011; 170: 1794–1803.
- 5 Davies MJ, Heller S, Skinner TC, Campbell MJ, Carey ME, Cradock S et al. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. Br Med J (Clin Res Ed) 2008; 336: 491–495.
- 6 National Screening Committee. *Handbook for Vascular Risk Assessment, Risk Reduction and Risk Management.* Department of Health: London, 2008.
- 7 Echouffo-Tcheugui JB, Simmons RK, Williams KM, Barling RS, Prevost AT, Kinmonth AL *et al*. The ADDITION-Cambridge trial protocol: a cluster – randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients. *BMC Public Health* 2009; **9**: 136.
- 8 Griffin SJ, Little PS, Hales CN, Kinmonth AL, Wareham NJ. Diabetes risk score: towards earlier detection of type 2 diabetes in general practice. *Diabetes Metab Res Rev* 2000; 16: 164–171.
- 9 Sargeant LA, Simmons RK, Barling RS, Butler R, Williams KM, Prevost AT *et al.* Who attends a UK diabetes screening programme? Findings from the ADDITION-Cambridge study. *Diabet Med* 2010; 27: 995–1003.
- 10 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* 1998; 15: 539–553.
- 11 Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbaek A *et al.* Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. *Lancet* 2011; 378: 156–167.
- 12 McIntosh A, Hutchinson A, Home PD, Brown F, Bruce A, Damerell A et al. Clinical Guidelines and Evidence for Type 2 Diabetes: Management of Blood Pressure. *Sheffield: School of Health and Related Research (ScHARR)*, 2002.
- 13 McIntosh A, Hutchinson A, Home PD, Brown F, Bruce A, Damerell A et al. Clinical Guidelines and Evidence for Type 2 Diabetes: Lipids Management. Sheffield: School of Health and Related Research (ScHAAR), 2002.
- 14 McIntosh A, Hutchinson A, Home PD, Brown F, Bruce A, Damerell A et al. Clinical Guidelines and Evidence Review for Type 2 Diabetes: Management of Blood Glucose. Sheffield: School of Health and Related Research (ScHAAR), 2001.
- 15 Coleman R, Stevens R., Holman R. The Oxford Risk Engine: a cardiovascular risk calculator for individuals with or without Type 2 diabetes. *Diabetes* 2007; 56 (Suppl 1): A170.
- 16 Wareham NJ, Jakes RW, Rennie KL, Mitchell J, Hennings S, Day NE. Validity and repeatability of the EPIC-Norfolk Physical Activity Questionnaire. *Int J Epidemiol* 2002; 31: 168–174.
- 17 Andrews RC, Cooper AR, Montgomery AA, Norcross AJ, Peters TJ, Sharp DJ *et al.* Diet or diet plus physical activity versus usual care in patients with newly diagnosed type 2 diabetes: the Early ACTID randomised controlled trial. *Lancet* 2011; 378: 129–139.